{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-262576","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.544499+00:00","generated_at":"2026-05-17T00:55:55.975430+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nuvation Bio Q3 net loss widens to $55.8M; first IBTROZI revenue $7.7M","bullets":["Net loss $55.8M ($0.16 loss per share) vs. $41.2M ($0.15) in Q3 2024.","Net product revenue from IBTROZI $7.7M; collaboration revenue $5.4M (up from $0.7M).","204 new patients started IBTROZI in Q3; median duration of response matured to 50 months.","Cash, cash equivalents, and marketable securities $549.0M at Sept 30, 2025.","First patients enrolled in TRUST-IV adjuvant study and safusidenib G203 study."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-262576","json":"https://secwatch.observer/filing/0001193125-25-262576.json","markdown":"https://secwatch.observer/filing/0001193125-25-262576.md","text":"https://secwatch.observer/filing/0001193125-25-262576.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525262576/0001193125-25-262576-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525262576/d21938d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:55:55.975430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}